BiotechTube

Rivoglitazone HCl + rivoglitazone HCl + rivoglitazone HCl + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type 2 Diabetes

Conditions

Type 2 Diabetes

Trial Timeline

Jul 1, 2007 → Mar 1, 2008

NCT ID
NCT00575471

About Rivoglitazone HCl + rivoglitazone HCl + rivoglitazone HCl + Placebo

Rivoglitazone HCl + rivoglitazone HCl + rivoglitazone HCl + Placebo is a phase 2 stage product being developed by Daiichi Sankyo for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT00575471. Target conditions include Type 2 Diabetes.

What happened to similar drugs?

20 of 20 similar drugs in Type 2 Diabetes were approved

Approved (20) Terminated (0) Active (0)
✅add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
✅Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
✅Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
✅exenatide and sitagliptin + exenatide and placeboEli LillyApproved
✅Tirzepatide + PlaceboEli LillyApproved
✅LisproEli LillyApproved
✅ToujeoMIRA PharmaceuticalsApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00575471Phase 2Completed

Competing Products

20 competing products in Type 2 Diabetes

See all competitors
ProductCompanyStageHype Score
NEX-22A, a prolonged release formulation of liraglutideNanexa ABPhase 1
23
DRL-17822 or placeboDr. Reddy's LaboratoriesPhase 2
32
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
29
MKP10241 + PlaceboMankind PharmaPhase 2
42
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
21
LY3209590 + Insulin DegludecEli LillyPhase 1
29
AC2993Eli LillyPhase 3
40
LY3209590 + PlaceboEli LillyPhase 1
29
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
40
LY2963016 + LantusEli LillyPhase 1
29
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
26
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
43
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
40
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
26
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
36
Placebo + LinagliptinEli LillyPhase 3
40
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
43
teplizumab or placeboEli LillyPhase 1
21
LY2428757 + PlaceboEli LillyPhase 2
35